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ABSTRACT
Leiomyosarcoma (LMS) of the vulva is rare. However it is the most common histologic
subtype of vulvar sarcoma, accounting for approximately 1% of all vulvar malignancies. [1-8] Whether genetics and epigenetics play a role in pathogenesis is unclear. [1]
The tumor is slow-growing with non-specific symptoms, has high metastatic potential,
and follows a bimodal age distribution. [1-8] Diagnosis and prognosis are based upon
immunohistochemical expression and criteria from early literature. [1,3,5-7] The most
common therapeutic approach involves radical vulvectomy with lymph node resection.
The value of adjuvant chemotherapy and radiation remains unknown. [1,3,5-8] Our case
describes a 46-year-old Caucasian G2P2 female with LMS of the left labia.
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BACKGROUND
Sarcomas of the vulva are relatively rare, accounting
for only 1-3% of all vulvar malignancies.1-8 They are
of mesenchymal origin and constitute a vast array of
histologic subtypes.1,5 Reported histologic variants
include leiomyosarcoma, rhabdomyosarcoma,
liposarcoma, angiosarcoma, malignant peripheral
nerve sheath tumor, malignant fibrous histiocytoma,
and epithelioid sarcoma.1,3,6
Of the above, leiomyosarcoma (LMS) is the most
common sarcoma subtype to involve the vulva. It
follows a bimodal age distribution with an average
age of 30-40 years old. The first mode represents
ages 20-30.1,3,5,6 Cases within this age group are
becoming increasingly prevalent, and whether this
has any correlation with reproductive hormones is in
question.1,5 The second mode affects a more elderly
population.1,2,8
The tumor is slow-growing with non-specific
symptoms and has high metastatic potential.2,3,8
Tumors may originate from the smooth muscle
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of blood vessels, tissue of the round ligament,
myoepithelium of Bartholin glands, or arrectorpili muscles.1,3,5 Pathogenesis related to genetic
predisposition and lifestyle are speculative due to the
prevalence of LMS in western countries.1
The following case describes a 46-year-old female
with LMS of the left labia. The rarity of LMS and
this patient’s deviation from the usual bimodal age
distribution makes this case of particular interest.
CASE REPORT
Our case is a 46-year-old Caucasian female, gravida
2, para 2, who presented with a painless mass of
the left labia majora situated between the left
Bartholin gland area and the posterior fourchette and
measuring around three cm with a solid consistency.
The patient’s medical history included menarche
at age ten and menopause at age 39 following a
partial hysterectomy for menorrhagia. Family history
included primary relatives with breast cancer and
melanoma. Several distant relatives were also
diagnosed with breast cancer, cervical cancer, and
prostate cancer. Genetic testing for the presence of
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disease was noted. However, the
pathology revealed few foci of
residual leiomyosarcoma associated
with procedural scar and persistently
positive margins. The final pathology
was consistent with FIGO stage 1B
vulvar leiomyosarcoma.

FIGURE 1. Cellular malignant spindle cell proliferation
arranged in intersecting fascicles (200x magnification).
alterations in 67 different cancer predisposition genes
associated with hereditary cancer syndromes only
revealed a variant of unknown significance, despite
her extensive family history of cancer. She denied
any history of smoking or previous contact with
hazardous materials.

She was given eight weeks to recover
from this procedure and then
underwent a third surgical procedure
which included examination under
anesthesia, bilateral inguinofemoral
lymph node dissection, and posterior
radical vulvectomy. Specimens
obtained included bilateral
inguinofemoral lymph nodes and a
radical excision of the posterior vulva
and scar with 1-2 cm margins down to endopelvic
fascia. No macroscopic evidence of inguinofemoral
lymph node involvement was noted during the
operation. Pathology revealed a focus of residual
leiomyosarcoma with negative margins and no
evidence of regional lymph node disease. The
patient’s postoperative course was uncomplicated.

She underwent an excisional procedure of her
left vulvar mass measuring a 3 x 2.5 cm with
a solid consistency. The pathology showed
a mitotically active malignant spindle cell
neoplasm with smooth muscle actin and
desmin expression (Figures 1-3). Tumor cells
were negative for cytokeratin AE1/AE3, p40,
S100, myogenin, myo-D1, caldesmon, CD34,
STAT-6, and TLE1. The histologic findings in
conjunction with the immunohistochemical
profile supported a diagnosis of
leiomyosarcoma with positive margins.
Following the initial excision, a PET-CT scan
revealed no evidence of metastatic disease
or pulmonary nodules. Uptake was only
present at the level of the labia. Further surgery was
indicated to excise the residual disease. A left partial
radical vulvectomy was performed and the vulvar
scar was removed with 1-2 cm of margin down to
the endopelvic fascia. No evidence of macroscopic
MARSHALL JOURNAL OF

MEDICINE
™

Expanding Knowledge to Improve Rural Health.

FIGURE 2. Tumor cells demonstrate moderate cytologic atypia in this high power field. Arrows mark
three mitotic figures (400x magnification).
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is equally sensitive and more specific
for classifying vulvovaginal smooth
muscle tumors according to patient
outcome.9 In this study, tumor necrosis
was also assessed as a valuable feature
for determining malignant potential.
Prognostication is based on mitotic
activity, tumor size and grade, pattern
of tumor interface, necrosis, and
metastatic spread.1,3,6,8,9

FIGURE 3. Spindled tumor cells show
immunoreactivity for Desmin (400x magnification).
DISCUSSION
Onset of vulvar LMS is often insidious. It may
arise from an existing leiomyoma, but most are
de novo.8 LMS presents clinically as a painless,
asymptomatic mass in early stages. The mass
is solid, ranging between 1.5 to 16 cm, and may
precipitate pain, bleeding, and voiding difficulty
with increased infiltration and size.1,3,5,6 The most
common localization is the labia majora, followed by
Bartholin gland, clitoris, and labia minora.3,5,6,7,8 Due
to the clinical presentation, LMS is often mistaken
for a more benign pathology: Bartholin gland cyst,
leiomyoma, lipoma, fibroma, infectious granuloma,
or myoma.2,3,5,6,7 Misdiagnosis delays treatment and
may provide potential for metastatic spread, so
considering LMS is always important.1,3,6,7
Diagnosis of LMS requires at least three of four
criteria, according to Nielsen et al.: (1) infiltrative
margins, (2) diameter >/= 5 cm, (3) moderate-tosevere (grade 2 or 3) cytologic atypia, or (4) >/= 5
mitotic figures per 10 high-power fields.1,3,5-7 Patients
with one or two of the above criteria meet the
diagnoses of leiomyoma and atypical leiomyoma,
respectively.3,6,7
Recent evidence suggests uterine criteria for LMS
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Muscle immunohistochemical
markers such as desmin and actin are
expressed in LMS, as exhibited by our
patient case. Other markers which
may be expressed include HHF-35,
caldesmon, and estrogen receptor
(ER). Ki-67 proliferation index is often
elevated.
Primary therapeutic recommendation is complete
surgical excision of the lesion with negative
margins, although there is no consensus on
surgical approach.1,3,5-8 The most common approach
involves radical vulvectomy with occasional lymph
node resection, which was performed in this
case.3 The value of lymphadenectomy in vulvar
leiomyosarcoma remains questionable and there
is no data supporting the routine performance of
lymphadenectomy in these cases.
Some case reports state that low-grade tumors
may require only wide local excision of the lesion
with negative margins.3,5 Other cases describe the
importance of radiation following radical vulvectomy
for tumors > 5 cm.3,5,6 Additional measures may
include radiation or chemotherapy at the discretion
of the oncologist. Necessity of adjuvant therapy
is unknown at this time, although it may decrease
risk of relapse and further metastatic spread.3,5,7
Recurrence and metastases have been reported
following radical vulvectomy with lymph node
resection.8
CONCLUSION
Leiomyosarcoma (LMS) is rare and insidious.
Incorporating this pathology into a differential
diagnosis is key when evaluating subcutaneous
vulvar lesions. Established diagnostic criteria
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and immunohistochemical stains aid in proper
identification. Early surgical excision with negative
margins and close follow-up decreases but does not
eliminate risk of metastasis and recurrence of LMS.
Further study is needed to better prognosticate and
adjunctively treat this potentially aggressive tumor.
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